References
Omuro AM et al. (2007) Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 6: 1909–1919
Mellinghoff IK et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353: 2012–2024
Shinojima N et al. (2003) Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63: 6962–6970
Liu L et al. (2005) Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med 83: 917–926
Pelloski CE et al. (2006) Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res 12: 3935–3941
Acknowledgements
The synopsis was written by Helen Jaques, Editorial Assistant, Nature Clinical Practice.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Omuro, A. What is the relevance of determining EGFR-variant-III status in glioblastomas?. Nat Rev Clin Oncol 5, 188–189 (2008). https://doi.org/10.1038/ncponc1074
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncponc1074
- Springer Nature Limited
This article is cited by
-
A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas
Journal of Neurology (2013)